Skip to main content

Quality of Life

  • Chapter
  • First Online:
Nail Psoriasis

Abstract

Nail psoriasis has been associated with significant impairment to health-related quality of life (HRQOL) affecting physical activities as well as emotional status and social behavior of patients. Impact of nail psoriasis on HRQOL is comparable to impact on HRQOL of other nail diseases and skin disorders. Improvement of nail psoriasis through systemic treatment results in significant improvement of HRQOL in psoriasis patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193:300–3.

    Article  PubMed  Google Scholar 

  2. Radtke MA, Langenbruch AK, Schäfer I, Herberger K, Reich K, Augustin M. Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas. 2011;2:1–6.

    PubMed  PubMed Central  Google Scholar 

  3. Feldman SR, Fleischer Jr AB, Reboussin DM, Rapp SR, Bradham DD, Exum ML, Clark AR. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37:564–9.

    Article  PubMed  CAS  Google Scholar 

  4. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233–9. doi:10.1002/art.24172.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163:580–5.

    Article  PubMed  CAS  Google Scholar 

  6. Ortonne JP, Baran R, Corvest M, et al. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24:22–7.

    Article  PubMed  CAS  Google Scholar 

  7. Belyayeva E, Gregoriou S, Chalikias J, Kontochristopoulos G, Koumantaki E, Makris M, Koti I, Katoulis A, Katsambas A, Rigopoulos D. The impact of nail disorders on quality of life. Eur J Dermatol. 2013;23(3):366–71.

    PubMed  Google Scholar 

  8. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:1–70. doi:10.1111/j.1468-3083.2009.03389.x. Erratum in: J Eur Acad Dermatol Venereol. 2010;24(1):117–8.

    Article  PubMed  Google Scholar 

  10. Torii H, Sato N, Yoshinari T, Nakagawa H, Japanese Infliximab Study Investigators. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol. 2012;39(3):253–9.

    Article  PubMed  CAS  Google Scholar 

  11. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008;159:453–6.

    Article  PubMed  CAS  Google Scholar 

  12. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol. 2010;24:530–4.

    Article  PubMed  CAS  Google Scholar 

  13. Rigopoulos D, Gregoriou S, Makris M, Ioannides D. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology. 2011;223:325–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dimitris Rigopoulos MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gregoriou, S., Rigopoulos, D. (2014). Quality of Life. In: Rigopoulos, D., Tosti, A. (eds) Nail Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-319-08810-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08810-5_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-08809-9

  • Online ISBN: 978-3-319-08810-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics